Denosumab biosimilar (Celltrion)

地舒单抗生物类似药 (Celltrion)

Report date: 2026/05/04 20:01:27

Base Information

Drug NameDenosumab biosimilar (Celltrion)
Drug Alias NameOsenveltStobocloCT-P41
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor ligand superfamily member 11 inhibitors
TargetsTumor necrosis factor ligand superfamily member 11
Therapy Area/IndicationsGlucocorticoid-induced osteoporosisBone ResorptionOsteoporosis, Postmenopausal +[8] 
Global Approved IndicationsGlucocorticoid-induced osteoporosisBone ResorptionOsteoporosis, Postmenopausal +[8] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2025/02/14
Country/TerritoryUnited StatesUkrainePoland +[8] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesCelltrion Inc
China Registration ClassN/A

Develop Information

Active CompaniesDaewoong Pharmaceutical Co LtdCelltrion Healthcare Hungary KftCelltrion Inc
Inactive CompaniesN/A
Active IndicationsGlucocorticoid-induced osteoporosisBone ResorptionOsteoporosis, Postmenopausal +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeM05BX04
Related LinksN/A